NCT01256073View on ClinicalTrials.gov

A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

July 31, 2013

Study Completion Date

September 30, 2013

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

IPH2101

IPH2101 fully human anti-KIR monoclonal antibody

Trial Locations (6)

13273

Institut Paoli-Calmettes, Marseille

31059

Hopital de Purpan, Toulouse

44093

C.H.R.U. de Nantes - Hotel Dieu, Nantes

69495

Centre Hospitalier Lyon Sud - Hospices Civils de Lyon, Pierre-Bénite

87042

Hopital Dupuytren, Limoges

94805

Institut Gustave Roussy, Villejuif

Sponsors

Lead Sponsor

Innate Pharma
All Listed Sponsors
lead

Innate Pharma

INDUSTRY